1.. INTRODUCTION
================

Disruption of circadian rhythms may be involved in the pathophysiology of psychiatric disorders, including drug addiction \[[@R1]-[@R7]\]. Several animal studies have shown that methamphetamine increased expression of circadian clock molecule genes such as *Per1*, *Per2*, *Bmal1*, and *Npas2*in the brain \[[@R8]-[@R10]\]. Recently, we detected the significant association between prokineticin 2 receptor gene (*PROKR2*) and Japanese methamphetamine dependence patients \[[@R11]\].

The prokineticin 2 (PK2) gene deficient mice showed reduced physiological and behavioral parameters, including circadian locomotor activity, circulating glucocorticoid, glucose levels and the expression of peripheral clock genes compared with WT mice \[[@R12]-[@R15]\]. The expression of PK2 gene in SCN was activated by the Clock/Bmal1 complex, and suppressed by Per/Cry *in vitro*studies \[[@R12]\]. This evidence indicate that PK2 gene (*PROK2*) is a good candidate gene for the pathogenesis of methamphetamine dependence. To evaluate the association between *PROK2* and methamphetamine dependence, we conducted a case-control study of Japanese samples (215 methamphetamine dependence and 232 controls) with four tagging SNPs selected by HapMap database.

2.. MATERIALS AND METHODS
=========================

2.1.. Subjects
--------------

The subjects in the association analysis were 215 METH deprendence patients (160 males and 39 females; mean age ± standard deviation (SD) 36.3 ± 11.4 years) and 232 healthy controls (187 males and 45 females; 36.4 ± 11.3 years). The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients. All subjects were unrelated to each other, ethnically Japanese, and lived in the central area of Japan. The patients were diagnosed according to DSM-IV criteria with consensus of at least two experienced psychiatrists on the basis of unstructured interviews and a review of medical records. One hundred ninety-seven of the subjects with METH dependence had a diagnosis of co-morbid METH induced psychosis. METH-induced psychosis patients were divided into two categories of psychosis prognosis, the transient type and the prolonged type, which showed remission of psychotic symptoms within 1 month and after more than 1 month, respectively, after the discontinuance of methamphetamine consumption and beginning of treatment with neuroleptics; 112 patients (56.9%) were the transient type, and 85 patients (42.1%) were the prolonged type. One hundred eighty-two subjects with METH-induced psychosis also had dependence on drugs other than METH. Cannabinoids were the most frequency abused drugs (21.4%), followed by cocaine (9.09%), LSD (9.09%), opioids (7.69%), and hypnotics (7.69%). Subjects with METH-induced psychosis were excluded if they had a clinical diagnosis of psychotic disorder, mood disorder, anxiety disorder or eating disorder. More detailed characterizations of these subjects have been published elsewhere \[[@R4],[@R16],[@R17]\]. All healthy controls were also psychiatrically screened based on unstructured interviews. None had severe medical complications such as liver cirrhosis, renal failure, heart failure or other Axis-I disorders according to DSM-IV.

The study was described to subjects and written informed consent was obtained from each. This study was approved by the Ethics Committee at Fujita Health University, Nagoya University School of Medicine and and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA).

2.2.. SNPs Selection and Linkage Disequilibrium (LD) Evaluation
---------------------------------------------------------------

We first consulted the HapMap database (release\#23a/phase II, March 2008, www.hapmap.org, population: Japanese Tokyo, minor allele frequencies (MAFs) of more than 0.05) and included 9 SNPs covering *PROK2* (5'-flanking regions including about 3100 bp from the initial exon and about 9800 bp downstream (3') from the last exon: HapMap database contig number chr3: 71894788.. 71919925). Four 'tagging SNPs' in *PROK2* was then selected with the criteria of r^2^ threshold greater than 0.8 in 'pair-wise tagging only' mode using the 'Tagger' program (Paul de Bakker, <http://www/broad.mit.edu/mpg/tagger>), in Haploview, for the following association analysis \[[@R18]\].

2.3.. SNPs Genotyping
---------------------

We used TaqMan assays (ABI: Applied Biosystems, Inc., Foster City, CA,) for all SNPs. One allelic probe was labeled with FAM dye and the other with the fluorescent VIC dye. The plates were heated for 2 min at 50°C and 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 58°C for 1 min. Please refer to ABI for the primer sequence. Detailed information is available on request.

2.4.. Statistical Analysis
--------------------------

Genotype deviation from the Hardy-Weinberg equilibrium (HWE) was evaluated by chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan).

Marker-trait association analysis was used to evaluate allele- and genotype-wise association with the chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan), and haplotype-wise association analysis was conducted with a likelihood ratio test using the COCAPHASE2.402 program \[[@R19]\]. We used the permutation test option as provided in the haplotype-wise analysis to avoid spurious results and correct for multiple testing. Permutation test correction was performed using 1000 iterations (random permutations). Power calculation was performed using a genetic power calculator \[[@R20]\]. The significance level for all statistical tests was 0.05.

3.. RESULTS
===========

The LD structure of *PROK2* from the HapMap database samples can be seen our previous paper \[[@R21]\]. Genotype frequencies of all SNPs were in HWE. We did not detect between all tagging SNPs and METH dependence in the Japanese population in the allele /genotype-wise (Table **[1](#T1){ref-type="table"}**) or haplotype-wise analysis (*P* ~haplotype~= 0.145). In addition, we found no association between four tagging SNPs and METH-induced psychosis patients in the allele /genotype-wise (Table **[1](#T1){ref-type="table"}**) or haplotype-wise analysis (*P* ~haplotype~= 0.225).

In the power analysis, we obtained more than 80% power for the detection of association when we set the genotype relative risk at 1.67-1.76 in METH dependence for *PROK2*under a multiplicative model of inheritance

4.. DISCUSSION
==============

We did not find an association between *PROK2* and Japanese METH dependence and METH-induced psychosis patients. Therefore, we reasoned that *PROK2* may not play an important role in the pathophysiology of METH dependence and METH-induced psychosis in the Japanese population. However, because our samples are small, we considered that there is a possibility of statistical error in these results.

We hypothesized that mood disorders and drug addiction have common susceptibility genes. For example, we detected the associations between prokineticin 2 receptor (*PROKR2*) and not only mood disorders including MDD and BP but also METH dependence and METH-induced psychosis in the Japanese population \[[@R11],[@R21]\]. Recently, Mohawk and colleagues reported that mice which were arrhythmic due to a lack of circadian clock genes showed circadian locomotor rhythms when treated with methamphetamine \[[@R22]\]. If patients with drug addiction disorders had disrupted circadian rhythms, it is possible that taking methamphetamine helps to restore circadian rhythms of taking into methamphetamine to keep to circadian rhythm. From this evidence, although we detected no association between *PROK2* and METH dependence and METH-induced psychosis, we consider that it will be necessary to conduct further investigation of the relationship between circadian clock genes and METH dependence and METH-induced psychosis.

A few points of caution should be mentioned with respect to our results. Firstly, the lack of association may be due to small sample size. Ideal samples for this study are METH use disorder samples with and without dependence and psychosis. Because we had only a few METH use disorder samples without dependence and psychosis, and we wanted to avoid statistical error, we did not perform an association analysis with these samples. Secondly, we did not include a mutation scan to detect rare variants. We designed the study based on the common disease-common variants hypothesis \[[@R23]\]. Further investigation will be required, such as medical resequencing using larger samples. However, statistical power is needed to evaluate the association of rare variants. To overcome these limitations, a replication study using larger samples or samples of other populations will be required for conclusive results \[[@R24],[@R25]\].

In conclusion, our results suggest that *PROK2* may not play a role in the pathophysiology of METH dependence in the Japanese population. However, because we did not perform a mutation scan of*PROK2*, a replication study using a larger sample may be required for conclusive results.
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Association Analysis of *PROK2* with Methamphetamine Dependence and Methamphetamine-Induced Psychosis

  SNP ID[a](#TF1){ref-type="table-fn"}   Phenotype[b](#TF2){ref-type="table-fn"}   MAF[c](#TF3){ref-type="table-fn"}   N       Genotype Distribution[d](#TF4){ref-type="table-fn"}   P-Value                              
  -------------------------------------- ----------------------------------------- ----------------------------------- ------- ----------------------------------------------------- --------- ----- ---- ------- ------- -------
  SNP1                                   rs1316780                                 Controls                            0.388   232                                                   87        110   35   0.183           
  T\>A                                   5'flanking region                         METH dependence                     0.347   215                                                   88        105   22   0.251   0.295   0.200
                                                                                   METH-induced psychosis              0.345   197                                                   82        94    21   0.436   0.357   0.196
  SNP2                                   rs10865660                                Controls                            0.358   232                                                   93        112   27   0.441           
  A\>G                                   intron2                                   METH dependence                     0.312   215                                                   99        98    18   0.360   0.320   0.144
                                                                                   METH-induced psychosis              0.358   197                                                   89        91    17   0.352   0.430   0.212
  SNP3                                   rs3796224                                 Controls                            0.183   232                                                   157       65    10   0.331           
  G\>A                                   intron2                                   METH dependence                     0.174   215                                                   148       59    8    0.490   0.936   0.733
                                                                                   METH-induced psychosis              0.183   197                                                   137       52    8    0.288   0.917   0.686
  SNP4                                   rs1374913                                 Controls                            0.394   232                                                   83        115   34   0.566           
  T\>G                                   3'flanking region                         METH dependence                     0.381   215                                                   80        106   29   0.512   0.917   0.690
                                                                                   METH-induced psychosis              0.381   197                                                   73        98    26   0.440   0.900   0.682

major allele\>minor allele

METH; methamphetamine

MAF: minor allele frequency

M: major allele, m: minor allele

Hardy-Weinberg equilibrium
